Energy and marine consultancy ABL has secured new five-year contracts with long-term client Woodside Energy that expands its existing workscope outside of Australia. ABL has been awarded a global ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific antibodies. ABL Bio will receive an upfront payment and potential milestone ...

Neuroscience isn't currently one of the top strategic R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The UK-headquartered pharma group is ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of Seoul-based ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly for its bispecific antibody ...

UK contract development and manufacturer organisation (CDMO) Oxford Biomedica confirmed this morning it is in talks that could result in the acquisition of rival ABL Europe from France’s Institut ...

Bispecific antibody specialist corporations ABL Bio said on the 14th that it signed an equity investment deal worth 22 billion won ($15 million) with U.S. pharmaceutical corporations Eli Lilly and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Compact and reliable, the ABL80 FLEX analyzer – BASIC version is a cost-effective choice for blood gas, electrolyte and lactate analysis. Its standby mode reduces the costs for consumables while the ...

The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize. For the second time in as many weeks, Eli Lilly is taking out its checkbook ...